P53 family: Therapeutic targets in neuroblastoma

Future Oncology

Volumn 6, Issue 3, 2010, Pages 429-444

  Wolter, Jennifer ^a   Angelini, Paola ^a   Irwin, Meredith ^a,b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apoptosis; Chemosensitivity; COX inhibitor; MTOR inhibitor; Neuroblastoma; Nutlin 3; P53 family; P63; P73

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; BIM PROTEIN; CAMPTOTHECIN; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEFEROXAMINE; DICLOFENAC; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; GEFITINIB; IRINOTECAN; MELPHALAN; METFORMIN; NUTLIN 3; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN MDM2; PROTEIN NOXA; PROTEIN P53; PROTEIN P63; PROTEIN P73; PUMA PROTEIN; RAPAMYCIN; TEMSIROLIMUS; TOPOTECAN; UNINDEXED DRUG; VALPROIC ACID; VINBLASTINE; VINCRISTINE;

ANTIANGIOGENIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER MORTALITY; CANCER RELAPSE; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME INACTIVATION; HUMAN; NEUROBLASTOMA; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN SYNTHESIS INHIBITION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL RATE;

ANIMALS; ANTINEOPLASTIC AGENTS; DNA-BINDING PROTEINS; HUMANS; NEUROBLASTOMA; NUCLEAR PROTEINS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 77949443432     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.09.176     Document Type: Review

References (168)

1. Maris JM, Hogarty MD, Bagatell R, Cohn SL: Neuroblastoma. Lancet 369, 2106-2120 (2007).
2. Tonini GP, Longo L, Coco S, Perri P: Familial neuroblastoma: a complex heritable disease. Cancer Lett. 197, 41-45 (2003).
3. Trochet D, Bourdeaut F, Janoueix-Lerosey I et al.: Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. Am. J. Hum. Genet. 74, 761-764 (2004).
4. van Limpt V, Schramm A, van Lakeman A et al.: The Phox2B homeobox gene is mutated in sporadic neuroblastomas. Oncogene 23, 9280-9288 (2004).
5. Chen Y, Takita J, Choi YL et al.: Oncogenic mutations of ALK kinase in neuroblastoma. Nature 455, 971-974 (2008).
6. George RE, Sanda T, Hanna M et al.: Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature 455, 975-978 (2008).
7. Janoueix-Lerosey I, Lequin D, Brugieres L et al.: Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 967-970 (2008).
8. Mosse YP, Laudenslager M, Longo L et al.: Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455, 930-935 (2008).
9. Diskin SJ, Hou C, Glessner JT et al.: Copy number variation at 1q21.1 associated with neuroblastoma. Nature 459, 987-991 (2009).
10. Maris JM, Mosse YP, Bradfield JP et al.: Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N. Engl. J. Med. 358, 2585-2593 (2008).
11. Birch JM, Alston RD, McNally RJ et al.: Relative frequency and morphology of cancers in carriers of germline TP53 mutations. Oncogene 20, 4621-4628 (2001).
12. Rossbach HC, Baschinsky D, Wynn T, Obzut D, Sutcliffe M, Tebbi C: Composite adrenal anaplastic neuroblastoma and virilizing adrenocortical tumor with germline TP53 R248W mutation. Pediatr. Blood Cancer 50, 681-683 (2008).
13. D'Angio GJ, Evans AE, Koop CE: Special pattern of widespread neuroblastoma with a favourable prognosis. Lancet 1, 1046-1049 (1971).
14. London WB, Castleberry RP, Matthay KK et al.: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J. Clin. Oncol. 23, 6459-6465 (2005).
15. Canete A, Gerrard M, Rubie H et al.: Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience. J. Clin. Oncol. 27, 1014-1019 (2009).
16. De Bernardi B, Gerrard M, Boni L et al.: Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification. J. Clin. Oncol. 27, 1034-1040 (2009).
17. Tonini GP, Boni L, Pession A et al.: MYCN oncogene amplification in neuroblastoma is associated with worse prognosis, except in stage 4s: the Italian experience with 295 children. J. Clin. Oncol. 15, 85-93 (1997).
18. Schneiderman J, London WB, Brodeur GM, Castleberry RP, Look AT, Cohn SL: Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group. J. Clin. Oncol. 26, 913-918 (2008).
19. Attiyeh EF, London WB, Mosse YP et al.: Chromosome 1p and 11q deletions and outcome in neuroblastoma. N. Engl. J. Med. 353, 2243-2253 (2005).
20. Brodeur GM, Minturn JE, Ho R et al.: Trk receptor expression and inhibition in neuroblastomas. Clin. Cancer Res. 15, 3244-3250 (2009).
21. Bown N, Cotterill S, Lastowska M et al.: Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N. Engl. J. Med. 340, 1954-1961 (1999).
22. Spitz R, Hero B, Ernestus K, Berthold F: Gain of distal chromosome arm 17q is not associated with poor prognosis in neuroblastoma. Clin. Cancer Res. 9, 4835-4840 (2003).
23. Shang X, Burlingame SM, Okcu MF et al.: Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol. Cancer Ther. 8, 2461-2469 (2009).
24. Liu X, Mazanek P, Dam V et al.: Deregulated Wnt/b-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 27, 1478-1488 (2008).
25. Valsesia-Wittmann S, Magdeleine M, Dupasquier S et al.: Oncogenic cooperation between H-Twist and N-Myc overrides failsafe programs in cancer cells. Cancer Cell 6, 625-630 (2004).
26. Stupack DG, Teitz T, Potter MD et al.: Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 439, 95-99 (2006).
27. Capasso M, Devoto M, Hou C et al.: Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat. Genet. 41, 718-723 (2009).
28. Janoueix-Lerosey I, Schleiermacher G, Michels E et al.: Overall genomic pattern is a predictor of outcome in neuroblastoma. J. Clin. Oncol. 27, 1026-1033 (2009).
29. Schleiermacher G, Michon J, Huon I et al.: Chromosomal CGH identifies patients with a higher risk of relapse in neuroblastoma without MYCN amplification. Br. J. Cancer 97, 238-246 (2007).
30. Cohn SL, Pearson AD, London WB et al.: The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. J. Clin. Oncol. 27, 289-297 (2009).
31. Brodeur GM, Maris JM: Neuroblastoma. In: Principles and Practice of Pediatric Oncology (5th Edition). Pizzo PA, Poplack DG (Eds). JB Lippincott, PA, USA, 933-970 (2006).
32. Gilman AL, Ozkaynak MF, Matthay KK et al.: Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the Children's Oncology Group. J. Clin. Oncol. 27, 85-91 (2009).
33. Garaventa A, Parodi S, De Bernardi B et al.: Outcome of children with neuroblastoma after progression or relapse. A retrospective study of the Italian neuroblastoma registry. Eur. J. Cancer 45(16), 2835-2842 (2009).
34. Irwin MS: Family feud in chemosensitvity: p73 and mutant p53. Cell Cycle 3, 319-323 (2004).
35. Bourdon JC, Fernandes K, Murray-Zmijewski F et al.: p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19, 2122-2137 (2005).
36. Moll UM, Slade N: p63 and p73: roles in development and tumor formation. Mol. Cancer Res. 2, 371-386 (2004).
37. Gonzalez S, Perez-Perez MM, Hernando E, Serrano M, Cordon-Cardo C: p73b-mediated apoptosis requires p57kip2 induction and IEX-1 inhibition. Cancer Res. 65, 2186-2192 (2005).
38. Zhu J, Jiang J, Zhou W, Chen X: The potential tumor suppressor p73 differentially regulates cellular p53 target genes. Cancer Res. 58, 5061-5065 (1998).
39. Harris SL, Levine AJ: The p53 pathway: positive and negative feedback loops. Oncogene 24, 2899-2908 (2005).
40. Vazquez A, Bond EE, Levine AJ, Bond GL: The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 7, 979-987 (2008).
41. Deyoung MP, Ellisen LW: p63 and p73 in human cancer: defining the network. Oncogene 26, 5169-5183 (2007).
42. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD: An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289, 304-306 (2000).
43. Stiewe T, Theseling CC, Putzer BM: Transactivation-deficient D TA-p73 inhibits p53 by direct competition for DNA binding: implications for tumorigenesis. J. Biol. Chem. 277, 14177-14185 (2002).
44. Melino G, De Laurenzi V, Vousden KH: p73: friend or foe in tumorigenesis. Nat. Rev. Cancer 2, 605-615 (2002).
45. Nakagawa T, Takahashi M, Ozaki T et al.: Autoinhibitory regulation of p73 by D Np73 to modulate cell survival and death through a p73-specific target element within the D Np73 promoter. Mol. Cell. Biol. 22, 2575-2585 (2002).
46. Stommel JM, Wahl GM: Accelerated MDM2 auto-degradation induced by DNA-damage kinases is required for p53 activation. EMBO J. 23, 1547-1556 (2004).
47. Stommel JM, Wahl GM: A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 4, 411-417 (2005).
48. Meulmeester E, Maurice MM, Boutell C et al.: Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2. Mol. Cell 18, 565-576 (2005).
49. Watson IR, Li BK, Roche O, Blanch A, Ohh M, Irwin MS: Chemotherapy induces NEDP1-mediated destabilization of MDM2. Oncogene 29(2), 297-304 (2009).
50. Watson IR, Irwin MS: Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia 8, 655-666 (2006).
51. Rossi M, Aqeilan RI, Neale M et al.: The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc. Natl Acad. Sci. USA 103, 12753-12758 (2006).
52. Rossi M, De Laurenzi V, Munarriz E et al.: The ubiquitin-protein ligase Itch regulates p73 stability. EMBO J. 24, 836-848 (2005).
53. Agami R, Blandino G, Oren M, Shaul Y: Interaction of c-Abl and p73a and their collaboration to induce apoptosis. Nature 399, 809-813 (1999).
54. Gong JG, Costanzo A, Yang HQ et al.: The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature 399, 806-809 (1999).
55. Yuan ZM, Shioya H, Ishiko T et al.: p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature 399, 814-817 (1999).
56. Irwin M, Marin MC, Phillips AC et al.: Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature 407, 645-648 (2000).
57. Gonzalez S, Prives C, Cordon-Cardo C: p73a regulation by Chk1 in response to DNA damage. Mol. Cell. Biol. 23, 8161-8171 (2003).
58. Urist M, Tanaka T, Poyurovsky MV, Prives C: p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes Dev. 18, 3041-3054 (2004).
59. Basu S, Totty NF, Irwin MS, Sudol M, Downward J: Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-13-3 and attenuation of p73-mediated apoptosis. Mol. Cell 11, 11-23 (2003).
60. Li Y, Peart MJ, Prives C: Stxbp4 regulates DNp63 stability by suppression of RACK1-dependent degradation. Mol. Cell. Biol. 29, 3953-3963 (2009).
61. Li Y, Zhou Z, Chen C: WW domain-containing E3 ubiquitin protein ligase 1 targets p63 transcription factor for ubiquitin-mediated proteasomal degradation and regulates apoptosis. Cell Death Differ. 15, 1941-1951 (2008).
62. Malkin D, Li FP, Strong LC et al.: Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250, 1233-1238 (1990).
63. Donehower LA, Harvey M, Slagle BL et al.: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356, 215-221 (1992).
64. Jacks T, Remington L, Williams BO et al.: Tumor spectrum analysis in p53-mutant mice. Curr. Biol. 4, 1-7 (1994).
65. Lang GA, Iwakuma T, Suh YA et al.: Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell 119, 861-872 (2004).
66. Olive KP, Tuveson DA, Ruhe ZC et al.: Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860 (2004).
67. Di Como CJ, Gaiddon C, Prives C: p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19, 1438-1449 (1999).
68. Marin MC, Jost CA, Brooks LA et al.: A common polymorphism acts as an intragenic modifier of mutant p53 behaviour. Nat. Genet. 25, 47-54 (2000).
69. Strano S, Fontemaggi G, Costanzo A et al.: Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem. 277, 18817-18826 (2002).
70. Flores ER, Sengupta S, Miller JB et al.: Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 7, 363-373 (2005).
71. Tomasini R, Tsuchihara K, Wilhelm M et al.: TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes Dev. 22, 2677-2691 (2008).
72. Suh EK, Yang A, Kettenbach A et al.: p63 protects the female germ line during meiotic arrest. Nature 444, 624-628 (2006).
73. de Vries A, Flores ER, Miranda B et al.: Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc. Natl Acad. Sci. USA 99, 2948-2953 (2002).
74. Lowe SW, Bodis S, McClatchey A et al.: p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810 (1994).
75. Brosh R, Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 9(10), 701-713 (2009).
76. Flores ER, Tsai KY, Crowley D et al.: p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416, 560-564 (2002).
77. Bergamaschi D, Gasco M, Hiller L et al.: p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387-402 (2003).
78. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG Jr: Chemosensitivity linked to p73 function. Cancer Cell 3, 403-410 (2003).
79. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW: p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 9, 45-56 (2006).
80. Hosoi G, Hara J, Okamura T et al.: Low frequency of the p53 gene mutations in neuroblastoma. Cancer 73, 3087-3093 (1994).
81. Komuro H, Hayashi Y, Kawamura M et al.: Mutations of the p53 gene are involved in Ewing's sarcomas but not in neuroblastomas. Cancer Res. 53, 5284-5288 (1993).
82. Vogan K, Bernstein M, Leclerc JM et al.: Absence of p53 gene mutations in primary neuroblastomas. Cancer Res. 53, 5269-5273 (1993).
83. Carr J, Bell E, Pearson AD et al.: Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res. 66, 2138-2145 (2006).
84. Slack A, Chen Z, Tonelli R et al.: The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in neuroblastoma. Proc. Natl Acad. Sci. USA 102, 731-736 (2005).
85. Cattelani S, Defferrari R, Marsilio S et al.: Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients. Clin. Cancer Res. 14, 3248-3253 (2008).
86. Perfumo C, Parodi S, Mazzocco K et al.: Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma. Eur. J. Cancer 44, 2634-2639 (2008).
87. Lau L, Hansford LM, Cheng LS et al.: Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene 26, 1920-1931 (2007).
88. Moll UM, Ostermeyer AG, Haladay R, Winkfield B, Frazier M, Zambetti G: Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. Mol. Cell. Biol. 16, 1126-1137 (1996).
89. Becker K, Marchenko ND, Maurice M, Moll UM: Hyperubiquitylation of wild-type p53 contributes to cytoplasmic sequestration in neuroblastoma. Cell Death Differ. 14, 1350-1360 (2007).
90. Nikolaev AY, Li M, Puskas N, Qin J, Gu W: Parc: a cytoplasmic anchor for p53. Cell 112, 29-40 (2003).
91. Keshelava N, Seeger RC, Groshen S, Reynolds CP: Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res. 58, 5396-5405 (1998).
92. Keshelava N, Zuo JJ, Chen P et al.: Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res. 61, 6185-6193 (2001).
93. Chesler L, Goldenberg DD, Collins R et al.: Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia 10, 1268-1274 (2008).
94. Kurata K, Yanagisawa R, Ohira M, Kitagawa M, Nakagawara A, Kamijo T: Stress via p53 pathway causes apoptosis by mitochondrial Noxa upregulation in doxorubicin-treated neuroblastoma cells. Oncogene 27, 741-754 (2008).
95. Xue C, Haber M, Flemming C et al.: p53 determines multidrug sensitivity of childhood neuroblastoma. Cancer Res. 67, 10351-10360 (2007).
96. Burkhart CA, Watt F, Murray J et al.: Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma. Cancer Res. 69, 6573-6580 (2009).
97. Okawa ER, Gotoh T, Manne J et al.: Expression and sequence analysis of candidates for the 1p36.31 tumor suppressor gene deleted in neuroblastomas. Oncogene 27, 803-810 (2008).
98. Schlisio S, Kenchappa RS, Vredeveld LC et al.: The kinesin KIF1Bb acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 22, 884-893 (2008).
99. White PS, Thompson PM, Gotoh T et al.: Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene 24, 2684-2694 (2005).
100. Ichimiya S, Nimura Y, Kageyama H et al.: p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent. Oncogene 18, 1061-1066 (1999).
101. Kovalev S, Marchenko N, Swendeman S, LaQuaglia M, Moll UM: Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth Differ. 9, 897-903 (1998).
102. Takada N, Ozaki T, Ichimiya S, Todo S, Nakagawara A: Identification of a transactivation activity in the COOH-terminal region of p73 which is impaired in the naturally occurring mutants found in human neuroblastomas. Cancer Res. 59, 2810-2814 (1999).
103. Ichimiya S, Nimura Y, Kageyama H et al.: Genetic analysis of p73 localized at chromosome 1p36.3 in primary neuroblastomas. Med. Pediatr. Oncol. 36, 42-44 (2001).
104. Banelli B, Casciano I, Romani M: Methylation-independent silencing of the p73 gene in neuroblastoma. Oncogene 19, 4553-4556 (2000).
105. Kong XT, Valentine VA, Rowe ST et al.: Lack of homozygously inactivated p73 in single-copy MYCN primary neuroblastomas and neuroblastoma cell lines. Neoplasia 1, 80-89 (1999).
106. Casciano I, Banelli B, Croce M et al.: Role of methylation in the control of DNp73 expression in neuroblastoma. Cell Death Differ. 9, 343-345 (2002).
107. Casciano I, Mazzocco K, Boni L et al.: Expression of DNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 9, 246-251 (2002).
108. Douc-Rasy S, Barrois M, Echeynne M et al.: DN-p73a accumulates in human neuroblastic tumors. Am. J. Pathol 160, 631-639 (2002).
109. Fillippovich I, Sorokina N, Gatei M et al.: Transactivation-deficient p73a (p73Dexon2) inhibits apoptosis and competes with p53. Oncogene 20, 514-522 (2001).
110. Nakagawa T, Takahashi M, Ozaki T et al.: Negative autoregulation of p73 and p53 by DNp73 in regulating differentiation and survival of human neuroblastoma cells. Cancer Lett. 197, 105-109 (2003).
111. Romani M, Tonini GP, Banelli B et al.: Biological and clinical role of p73 in neuroblastoma. Cancer Lett. 197, 111-117 (2003).
112. Lau LM, Wolter JK, Lau JT et al.: Cyclooxygenase inhibitors differentially modulate p73 isoforms in neuroblastoma. Oncogene 28, 2024-2033 (2009).
113. Stiewe T, Putzer BM: Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat. Genet. 26, 464-469 (2000).
114. Zhu X, Wimmer K, Kuick R et al.: N-myc modulates expression of p73 in neuroblastoma. Neoplasia 4, 432-439 (2002).
115. Maisse C, Munarriz E, Barcaroli D, Melino G, De Laurenzi V: DNA damage induces the rapid and selective degradation of the DNp73 isoform, allowing apoptosis to occur. Cell Death Differ. 11, 685-687 (2004).
116. Hosoda M, Ozaki T, Miyazaki K et al.: UFD2a mediates the proteasomal turnover of p73 without promoting p73 ubiquitination. Oncogene 24, 7156-7169 (2005).
117. Lee AF, Ho DK, Zanassi P, Walsh GS, Kaplan DR, Miller FD: Evidence that DNp73 promotes neuronal survival by p53- dependent and p53-independent mechanisms. J. Neurosci. 24, 9174-9184 (2004).
118. De Laurenzi V, Raschella G, Barcaroli D et al.: Induction of neuronal differentiation by p73 in a neuroblastoma cell line. J. Biol. Chem. 275, 15226-15231 (2000).
119. Lau LM, Nugent JK, Zhao X, Irwin MS: HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene 27, 997-1003 (2008).
120. Simoes-Wust AP, Sigrist B, Belyanskaya L, Hopkins Donaldson S, Stahel RA, Zangemeister-Wittke U: DNp73 antisense activates PUMA and induces apoptosis in neuroblastoma cells. J. Neurooncol. 72, 29-34 (2005).
121. Million K, Horvilleur E, Goldschneider D et al.: Differential regulation of p73 variants in response to cisplatin treatment in SH-SY5Y neuroblastoma cells. Int J. Oncol. 29, 147-154 (2006).
122. Santos A, Calvet L, Terrier-Lacombe MJ et al.: In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations. Cancer Res. 64, 3223-3229 (2004).
123. Vassilev LT: MDM2 inhibitors for cancer therapy. Trends Mol. Med. 13, 23-31 (2007).
124. Tovar C, Rosinski J, Filipovic Z et al.: Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc. Natl Acad. Sci. USA 103, 1888-1893 (2006).
125. Vassilev LT, Vu BT, Graves B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
126. van Maerken T, Speleman F, Vermeulen J et al.: Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma. Cancer Res. 66, 9646-9655 (2006).
127. Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F: E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. Oncogene 27, 5303-5314 (2008).
128. Laurie NA, Donovan SL, Shih CS et al.: Inactivation of the p53 pathway in retinoblastoma. Nature 444, 61-66 (2006).
129. Coll-Mulet L, Iglesias-Serret D, Santidrian AF et al.: MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. Blood 107, 4109-4114 (2006).
130. Barbieri E, Mehta P, Chen Z et al.: MDM2 inhibition sensitizes neuroblastoma to chemotherapy-induced apoptotic cell death. Mol. Cancer Ther. 5, 2358-2365 (2006).
131. Peirce SK, Findley HW: The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J. Oncol. 34, 1395-1402 (2009).
132. Dempke W, Rie C, Grothey A, Schmoll HJ: Cyclooxygenase-2: a novel target for cancer chemotherapy? J. Cancer Res. Clin. Oncol. 127, 411-417 (2001).
133. Johnsen JI, Lindskog M, Ponthan F et al.: Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. Cancer Res. 64, 7210-7215 (2004).
134. Ponthan F, Wickstrom M, Gleissman H et al.: Celecoxib prevents neuroblastoma tumor development and potentiates the effect of chemotherapeutic drugs in vitro and in vivo. Clin. Cancer Res. 13, 1036-1044 (2007).
135. Rosenbluth JM, Mays DJ, Pino MF, Tang LJ, Pietenpol JA: A gene signature-based approach identifies mTOR as a regulator of p73. Mol. Cell. Biol. 28, 5951-5964 (2008).
136. Sooriakumaran P, Macanas-Pirard P, Bucca G et al.: A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer. Cancer Genomics Proteomics 6, 93-99 (2009).
137. Bresalier RS, Sandler RS, Quan H et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102 (2005).
138. Schonthal AH, Chen TC, Hofman FM, Louie SG, Petasis NA: Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs. Expert Opin. Investig. Drugs 17, 197-208 (2008).
139. Lamb J: The Connectivity Map: a new tool for biomedical research. Nat. Rev. Cancer 7, 54-60 (2007).
140. Rosenbluth JM, Pietenpol JA: mTOR regulates autophagy-associated genes downstream of p73. Autophagy 5, 114-116 (2009).
141. Johnsen JI, Segerstrom L, Orrego A et al.: Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo. Oncogene 27, 2910-2922 (2008).
142. Kurmasheva RT, Harwood FC, Houghton PJ: Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol. Cancer Ther. 6, 1620-1628 (2007).
143. Marimpietri D, Brignole C, Nico B et al.: Combined therapeutic effects of vinblastine and rapamycin on human neuroblastoma growth, apoptosis, and angiogenesis. Clin. Cancer Res. 13, 3977-3988 (2007).
144. Marimpietri D, Nico B, Vacca A et al.: Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene 24, 6785-6795 (2005).
145. Amin AR, Paul RK, Thakur VS, Agarwal ML: A novel role for p73 in the regulation of Akt-Foxo1a-Bim signaling and apoptosis induced by the plant lectin, concanavalin A. Cancer Res. 67, 5617-5621 (2007).
146. Wagner LM, Danks MK: New therapeutic targets for the treatment of high-risk neuroblastoma. J. Cell. Biochem. 107(1), 46-57 (2009).
147. Goodwin PJ, Ligibel JA, Stambolic V: Metformin in breast cancer: time for action. J. Clin. Oncol. 27, 3271-3273 (2009).
148. Garcia-Gil M, Bertini F, Pesi R, Voccoli V, Tozzi MG, Camici M: 5′-amino-4- imidazolecarboxamide riboside induces apoptosis in human neuroblastoma cells via the mitochondrial pathway. Nucleosides Nucleotides Nucleic Acids 25, 1265-1270 (2006).
149. Brodie C, Siriwardana G, Lucas J et al.: Neuroblastoma sensitivity to growth inhibition by deferrioxamine: evidence for a block in G1 phase of the cell cycle. Cancer Res. 53, 3968-3975 (1993).
150. Blatt J: Deferoxamine in children with recurrent neuroblastoma. Anticancer Res. 14, 2109-2112 (1994).
151. Donfrancesco A, De Bernardi B, Carli M et al. Italian Neuroblastoma Cooperative Group: Deferoxamine followed by cyclophosphamide, etoposide, carboplatin, thiotepa, induction regimen in advanced neuroblastoma: preliminary results. Eur. J. Cancer 31A, 612-615 (1995).
152. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL: Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br. J. Pharmacol 153, 657-668 (2008).
153. Muscolini M, Cianfrocca R, Sajeva A et al.: Trichostatin A up-regulates p73 and induces Bax-dependent apoptosis in cisplatin-resistant ovarian cancer cells. Mol. Cancer Ther. 7, 1410-1419 (2008).
154. Ho R, Minturn JE, Hishiki T et al.: Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. 65, 9868-9875 (2005).
155. Rossler J, Odenthal E, Geoerger B et al.: EGFR inhibition using gefitinib is not active in neuroblastoma cell lines. Anticancer Res. 29, 1327-1333 (2009).
156. Tamura S, Hosoi H, Kuwahara Y et al.: Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells. Biochem. Biophys. Res. Commun 358, 226-232 (2007).
157. Freeman BB 3rd, Daw NC, Geyer JR, Furman WL, Stewart CF: Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest 24, 310-317 (2006).
158. Dicker F, Kater AP, Prada CE et al.: CD154 induces p73 to overcome the resistance to apoptosis of chronic lymphocytic leukemia cells lacking functional p53. Blood 108, 3450-3457 (2006).
159. Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ: Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression. J. Natl Cancer Inst 96, 46-55 (2004).
160. Naruganahalli KS, Lakshmanan M, Dastidar SG, Ray A: Therapeutic potential of Aurora kinase inhibitors in cancer. Curr. Opin. Investig. Drugs 7, 1044-1051 (2006).
161. Tao Y, Zhang P, Frascogna V et al.: Enhancement of radiation response by inhibition of Aurora-A kinase using siRNA or a selective Aurora kinase inhibitor PHA680632 in p53-deficient cancer cells. Br. J. Cancer 97, 1664-1672 (2007).
162. Dar AA, Belkhiri A, Ecsedy J, Zaika A, El-Rifai W: Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells. Cancer Res. 68, 8998-9004 (2008).
163. Otto T, Horn S, Brockmann M et al.: Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma. Cancer Cell 15, 67-78 (2009).
164. Lambert JM, Gorzov P, Veprintsev DB et al.: PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15, 376-388 (2009).
165. Kravchenko JE, Ilyinskaya GV, Komarov PG et al.: Small-molecule RETRA suppresses mutant p53-bearing cancer cells through a p73-dependent salvage pathway. Proc. Natl Acad. Sci. USA 105, 6302-6307 (2008).
166. Bell HS, Ryan KM: iASPP inhibition: increased options in targeting the p53 family for cancer therapy. Cancer Res. 68, 4959-4962 (2008).
167. Asgharzadeh S, Pique-Regi R, Sposto R et al.: Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J. Natl Cancer Inst. 98, 1193-1203 (2006).
168. Vermeulen J, De Preter K, Naranjo A et al.: Predicting outcomes for children with neuroblastoma using a multigene-expression signature: a retrospective SIOPEN/COG/GPOH study. Lancet Oncol. 10, 663-671 (2009).